title: Effect of glycine on the immune response of the experimentally diabetic rats.
abstract: BACKGROUND
  Hyperglycemia induces protein glycation, disturbing its function, additionally, the glycated products (AGEs) induce by themselves proinflammatory cytokine release that are responsible for insulin resistance. Glycine has been successfully used in diabetic patients to competitively reduce hemoglobin glycation.
  
  
  OBJECTIVE
  To assess hyperglycemia impact on the immune response and to evaluate if it is possible to reverse it by means of glycine administration.
  
  
  METHODS
  Streptozotocin-induced diabetic rats, with and without glycine administration were challenged with sheep red blood cells, and specific antibody producing cells were accounted. Normal rats were challenged as controls.
  
  
  RESULTS
  Induced diabetes modifies significantly the humoral immune response capacity versus sheep red blood cells. Also, glycine administration prevents against this deleterious effect.
  
  
  CONCLUSIONS
  Glycine could be an important therapeutic resource among diabetics to avoid the characteristic immunodeficiencies of this disease.
authors.affiliation: Respiratory Diseases National Institute of Mexico, Xenotransplantation Laboratory, Infantile Hospital of Mexico Federico Gomez, Mexico. dianalm@iner.gob.mx
authors.forename: Diana
authors.initials: D
authors.lastname: Lezcano Meza
authors.forename: Luis
authors.initials: L
authors.lastname: Terán Ortiz
authors.forename: Guillermo
authors.initials: G
authors.lastname: Carvajal Sandoval
authors.forename: Mónica
authors.initials: M
authors.lastname: Gutiérrez de la Cadena
authors.forename: David
authors.initials: D
authors.lastname: Terán Escandón
authors.forename: Sergio
authors.initials: S
authors.lastname: Estrada Parra
mesh_terms: D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D000921:Antibody-Producing Cells / Q000187:drug effects / Q000276:immunology; D001786:Blood Glucose / Q000032:analysis; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000276:immunology*; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes / Q000276:immunology; D006442:Glycated Hemoglobin / Q000032:analysis; D017127:Glycation End Products, Advanced / Q000032:analysis; D005998:Glycine / Q000494:pharmacology / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012756:Sheep; D013311:Streptozocin
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D005998:Glycine; D013311:Streptozocin